SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: idos who wrote (2478)9/14/2010 4:28:25 AM
From: tuck  Read Replies (1) of 3027
 
Re: "Copolymer Assay"

Notable excerpt: "The present invention provides methods and compositions for evaluating one or more properties of a candidate agent (e.g., an amino acid copolymer, e.g., Copolymer-1; e.g., glatiramer acetate). In one aspect, the invention provides a variety of embodiments for evaluating an amino acid copolymer preparation for physiological, pharmacodynamic, pharmacokinetic, or pharmaceutical properties including but not limited to potency, specificity, stability, biological activity, e.g., for suitability as a pharmaceutical preparation, e.g., for the treatment of autoimmune and/or inflammatory disease, disorders or dysfunctions."

Although, looking at this, I see it's all in vitro, and I don't see the embodiments relating to PK and PD, that is, if they are there, I am not recognizing them as such. Would the FDA go for this?

wipo.int

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext